Press release
Amyotrophic Lateral Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Amyotrophic Lateral Sclerosis research. Learn more about our innovative pipeline today! @ Amyotrophic Lateral Sclerosis Pipeline Outlook [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
* In July 2025, Biojiva LLC announced a phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis.
* DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
* The leading Amyotrophic Lateral Sclerosis Companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics , UCB and others.
* Promising Amyotrophic Lateral Sclerosis Pipeline Therapies such as Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), RT001, ARGX-119, AMX0035, ION363, ANX005, and others.
Stay informed about the cutting-edge advancements in Amyotrophic Lateral Sclerosis treatments. Download for updates and be a part of the revolution in Neurology care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyotrophic Lateral Sclerosis Emerging Drugs Profile
* MN-166: MediciNova
MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1Ss, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of ALS.
* RNS60: Revalesio
RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
* VM202: Helixmith
VM202 is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. The drug is injected along the peripheral nerves and their branches, the internal production of HGF may protect nerves and promote the growth of neurons while also ameliorating atrophic conditions. The US FDA granted orphan drug and fast track designation to VM202. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
* QRL-201: QurAlis Corporation
QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the treatment of ALS.
The Amyotrophic Lateral Sclerosis Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
* Amyotrophic Lateral Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.
Learn more about Amyotrophic Lateral Sclerosis Drugs opportunities in our groundbreaking Amyotrophic Lateral Sclerosis research and development projects @ Amyotrophic Lateral Sclerosis Unmet Needs [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyotrophic Lateral Sclerosis Companies
Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics , UCB and others.
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Amyotrophic Lateral Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
* Coverage- Global
* Amyotrophic Lateral Sclerosis Companies- Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics , UCB and others.
* Amyotrophic Lateral Sclerosis Pipeline Therapies- Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), RT001, ARGX-119, AMX0035, ION363, ANX005, and others.
* Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Amyotrophic Lateral Sclerosis Pipeline on our website @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Amyotrophic Lateral Sclerosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Amyotrophic Lateral Sclerosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* MN-166: MediciNova
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* QRL-201: QurAlis Corporation
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Amyotrophic Lateral Sclerosis Key Companies
* Amyotrophic Lateral Sclerosis Key Products
* Amyotrophic Lateral Sclerosis- Unmet Needs
* Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
* Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
* Amyotrophic Lateral Sclerosis Analyst Views
* Amyotrophic Lateral Sclerosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyotrophic-lateral-sclerosis-pipeline-appears-robust-with-75-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4096646 • Views: …
More Releases from ABNewswire
BlackHawk Productions Launches Kickstarter for 'Tech Pt: ONE': A Groundbreaking …
Image: https://www.abnewswire.com/upload/2025/07/15124b54e799d203712478f5cc498e24.jpg
BlackHawk Productions proudly announces the launch of its upcoming feature film, Tech Pt: ONE, a dynamic, action-packed thriller that redefines representation in cinema. The film centers on Tech, a brilliant Black female special agent confined to a wheelchair, who must stop the powerful and vengeful Princess Zora from wreaking havoc on New Orleans.
The Kickstarter campaign officially launches on August 4, 2025, and supporters can join the movement here: https://www.kickstarter.com/projects/tech2025/tech-pt-one-feature-film.
Created…
Mid South Conference Announces New Streaming Partnership with Urban Edge Network
Image: https://www.abnewswire.com/upload/2025/07/00c0c0b90f2ca36063c51c05dec82085.jpg
July 16, 2025 - Bowling Green, KY - The Mid-South Conference (MSC) is thrilled to announce an exciting new streaming partnership with Urban Edge Network (UEN) to showcase the thrilling championship events of the conference. This collaboration signifies a groundbreaking step in elevating the visibility of MSAC sports through innovative streaming solutions.
Mid-South Conference Interim Commissioner Chris Wells said of the new deal, "This is a significant agreement that will…
Face-to-Face Counselling in Birmingham: The Benefits of Personalised Support
In today's fast-paced world, mental health has become an essential part of our overall well-being. Whether you're facing stress, anxiety, depression, or relationship issues, the decision to seek professional support can make all the difference. One of the most effective and personal ways to access counselling is through face-to-face counselling. In this article, we will explore how face to face counselling in Birmingham UK offers a unique, tailored approach to…
Maid Perfect Residential Home & Commercial Cleaning Service Expands Operations t …
Leading Los Angeles cleaning service provider increases capacity to meet growing demand across entire county, bringing professional residential and commercial cleaning solutions to over 10 million residents
LOS ANGELES, CA - July 15, 2025 - Maid Perfect Residential Home & Commercial Cleaning Service, a trusted provider of professional cleaning solutions in Los Angeles, today announced its expansion to serve all of Los Angeles County. This strategic growth initiative will bring the…
More Releases for Late
Desperate Puppy Seeks Rescue Before It’s Too Late!
FOR IMMEDIATE RELEASE
Tucson AZ, December 14th, 2021
The StarBarksCoffee.com rescue team was recently assaulted and threatened with being shot for assisting an abused, entangled puppy.
This Video of a neglected puppy desperately seeking rescue from a mentally unstable and violently aggressive owner was taken recently at an RV park in Texas during our annual "Journey Across America" in support of Animal Welfare.
We've contacted Texas authorities, but the Sheriff’s Department informed us the…
Transform your Traditional Businesses Before Its Too Late
Mob Inspire, an app development company has disrupted many industries by providing innovative software solutions to traditional businesses. We understand the rapidly changing tech environment and therefore equipt ourselves with those skills and tech tools which enable us to deal with challenging situations efficiently.
Mob Inspire takes the leverage of the latest tech trends like Blockchain, IoT and Cloud to deliver high-end products to its clients. The popularity…
May Tax Offices Collect 6% Interest for Late Payments
The 0% interest policy of the European Central Bank and German tax offices can still demand 6% default interest for late payments. How can this be? Is that not a crying injustice? The authorities collect 6% interest and all tax payers are punished when they save money in bank accounts with, for example, -1% interest. The Federal Fiscal Court ruled on this matter on November 09, 2017 (re III R…
Late-Night Treats for Late-Night Peeps
WHAT: La Motta’s, the neighborhood favorite in Boston’s SoWa District, is rolling out the late-night red carpet for its hospitality industry folks and friends, with Chef de Cuisine Justin Winter’s creative twists on after-hours snacks. Available every Sunday - Thursday from 10:00PM to last call, La Motta’s is the neighborhood joint for a late-night bash with flavorful bites and brews.
Launching Sunday, February 26th, 2017, guests can expect flavorful options…
Late payment – the hidden challenge facing Europe's businesses
A recent Europe-wide business survey has revealed no improvement in the pressure on European businesses from customers’ late payments, with 55 per cent of businesses across Europe reporting late payments resulting in loss of income, 63 per cent claiming additional pressures on liquidity, and 50 per cent citing late payments as having a direct impact on company growth.
In the Republic of Ireland, 47 per cent of businesses surveyed claimed…
Construction in Bulgaria to stabilise in late 2011
In the coming years Bulgaria's construction sector will start to grow slowly following the hard years of the economic slowdown, although no spectacular changes are expected in the short run. After substantial restructuring of the sector moderate construction market recovery in the period 2012-2013 is expected. Until 2015 the sector will grow on the back of the large-scale infrastructure projects related to EU funds.
According to the report “Construction sector in…
